Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Health Care Workers Cohort Study in the EuCARE Project (EuCARE-HCW)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The WP3 healthcare workers cohort in EuCARE is an observational multicentre study including collection of retrospective (historical) and prospective data and sample collection from health care workers with either a vaccination or a confirmed SARS-CoV-2 infection. Samples from HCW are sent to central laboratories for WP2 study were the impact of different variants in humoral and cellular immunity is to be analysed by biostatistical methods and with artificial intelligence in WP5. This analysis will focus on the impact on vaccine escape of viral variants / viral sequences as well as on any escape from any combination of natural and vaccine induced immunity. Eight countries will participate (Portugal, Italy, Germany, Lithuania, Georgia, Russia, Vietnam and Mexico).

Who May Be Eligible (Plain English)

Who May Qualify: The study subjects will be selected based on the following Who May Qualify: 1. Adult (\>18 years) HCW with mandatory information on their SARS-CoV-2 infection and vaccination status. 2. For those with a history of SARS-CoV-2 infection, diagnosis obtained by detection of SARS-CoV-2 RNA 3. Having a signed willing to sign a consent form when required by ethical approval Who Should NOT Join This Trial: NONE Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: The study subjects will be selected based on the following inclusion criteria: 1. Adult (\>18 years) HCW with mandatory information on their SARS-CoV-2 infection and vaccination status. 2. For those with a history of SARS-CoV-2 infection, diagnosis obtained by detection of SARS-CoV-2 RNA 3. Having a signed informed consent when required by ethical approval Exclusion Criteria: NONE

Treatments Being Tested

OTHER

Follow up of the first known immunization event

The baseline for enrolment into the study is defined by the occurrence of the first known immunization event, either natural infection or vaccination. The follow-up is planned to last 24 months with respect to this baseline. In subjects with natural infection, the viral variant must be determined for each prospective case by analysis of a nasopharyngeal swab obtained as soon as possible at diagnosis. For historical cases where the variant was not determined and a contemporary nasopharyngeal swab has not been stored, the viral variant may be inferred when a specific variant was dominating the geographic area according to official records available at local health agencies. However, the variant assignment will be labelled as putative, rather than proved. HCWs can be enrolled in the category of: (i) vaccination not followed by any later infection, (ii) infection followed by vaccination and (iii) vaccination followed by infection.

Locations (7)

Heinrich Heine university
Düsseldorf, Germany
Azienda Socio-Sanitaria Territoriale Santi Paolo e Carlo
Milan, Italy
Ieo Istituto Europeo Di Oncologia
Milan, Italy
Viesoji Istaiga Vilniaus Uiversiteto Ligoninė Santaros klinikos
Vilnius, Lithuania
Hospital Juan Ghaham Casasus
Villahermosa, Mexico
Centro Hospitalar de Lisboa Ocidental
Lisbon, Portugal
Bach Mai Hospital
Hanoi, Vietnam